Patients' Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb).

MLA

Seng, Elizabeth, et al. “Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (MAb).” Pain & Therapy, vol. 13, no. 6, Dec. 2024, pp. 1589–615. EBSCOhost, https://doi.org/10.1007/s40122-024-00652-z.

APA

Seng, E., Lampl, C., Viktrup, L., Lenderking, W. R., Karn, H., Hoyt, M., Kim, G., Ruff, D., Ossipov, M. H., & Vincent, M. (2024). Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb). Pain & Therapy, 13(6), 1589–1615. https://doi.org/10.1007/s40122-024-00652-z

Chicago

Seng, Elizabeth, Christian Lampl, Lars Viktrup, William R. Lenderking, Hayley Karn, Margaret Hoyt, Gilwan Kim, Dustin Ruff, Michael H. Ossipov, and Maurice Vincent. 2024. “Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (MAb).” Pain & Therapy 13 (6): 1589–1615. doi:10.1007/s40122-024-00652-z.